ClinicalTrials.gg
Active, not recruitingNCT03626038Updated Feb 13, 2026

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

An interventional study of A.L.P.S. Proximal Humerus Plating System in Osteoarthritis, Rheumatoid Arthritis and Post-Traumatic Arthritis, sponsored by Zimmer Biomet. Active, not recruiting at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Zimmer Biomet · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 101 studies in Osteoarthritis by Zimmer Biomet — 4 open to participants now, 24 under way, none of them phase 3. Osteoarthritis · Zimmer Biomet.

Enrollment
23rd of 48
135 · median 133
Started
2018
with 2 others
No phase
46 of 101
1 open now
Primary completion
2026-12
later than 3 of 23 live
Registered
86th of 101
by date

Among the 101 studies in Osteoarthritis by Zimmer Biomet, this one is the 23rd largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2018, is one of 46 with no phase, reaches primary completion later than 3 of the 23 other live ones, and was the 86th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

4 of the 101 studies in Osteoarthritis by Zimmer Biomet are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Osteoarthritis by Zimmer Biomet, or all of them as a file.
02

Study summary

This study is a multicenter, prospective, non-randomized, non-controlled post-market clinical follow-up study. The primary objective of this study is to confirm the safety and performance of the A.L.P.S. Proximal Humerus Plating System applied in proximal humerus fracture treatment.

Read the detailed description

The A.L.P.S. Proximal Humerus Plating System was developed to provide another surgical option for proximal humerus fracture fixation. The aim of the A.L.P.S. Proximal Humerus Plating System is to provide increased fracture stability while simultaneously increasing range of motion and decreasing the likelihood of screw perforation.

A minimum of 7 and maximum of 10 sites globally will be involved in this study. This number of clinical sites will allow for a better generalization of study data as well as allow for consistency to be developed across multiple regions. 135 implants will be included into the study. Each site will be allowed to enroll 27 humeri. Enrollment is competitive. All potential study subjects will be required to participate in the Informed Consent process.

03

Conditions studied

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Post-Traumatic Arthritis
  • Psoriatic Arthritis
  • Proximal Humeral Fracture

Keywords

  • Trauma
  • Medical Device
  • Performance
  • Safety
  • Proximal Humeral Fracture
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 years of age or older.
  • Patient must have a primary proximal humerus fracture (Orthopaedic Trauma Association/ American Orthopedic 11-A, B, C) requiring surgical intervention and be eligible for fixation by plate and screws.
  • Patients with failed conservative treatment within 3 weeks since injury.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must have a signed Institutional Review Board/Ethics Committee approved .
  • Patient must be in a good nutritional state

Exclusion criteria

Exclusion Criteria:

  • Delay of surgery for more than 3 weeks.
  • Tumor induced fractures
  • Patient is a prisoner.
  • Pregnancy/ breast feeding
  • Patient is a current alcohol or drug abuser.
  • Patient has a mental or neurologic condition that will not allow for proper and/or participation in follow-up program.
  • Patient has an active infection.
  • Patient conditions including limitations in blood supply, obesity, or insufficient quantity or quality of bone stock.
  • Patient is sensitive to foreign body material.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.

    Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System. Subjects can be enrolled prospectively or retrospectively as indicated in the protocol.

    Device: A.L.P.S. Proximal Humerus Plating System

Interventions

  • DeviceA.L.P.S. Proximal Humerus Plating System

    Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.

06

What researchers measure

Primary outcomes

  1. Re-operation

    Re--operation within the first year post-initial surgery due to screw perforation of the humeral head, secondary displacement or impingement to relieve pain and/or improve function.

    Time frame: 1 year

Secondary outcomes

  1. Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeon Patient Questionnaire

    Pain, function and activities of daily living are measured. The American Shoulder and Elbow Surgeon (ASES) scale is 0 to 100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.

    Time frame: 2 years

  2. Shoulder range of motion measurement

    Shoulder range of motion is assessed in degrees of directional movement. This will be measured during a physical exam by the investigator. Values measured include active and passive range of motion.

    Time frame: 2 years

  3. Clinical performance of the device is assessed using x-ray capture

    X-ray capture will be used to analyze fracture healing

    Time frame: 2 years

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Dec 2026, 102 months after the start.

Of 135 industry-sponsored interventional studies with no phase under Osteoarthritis, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 81. This study's planned 102 months is above that.

Counting every sponsor, half of 711 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2018
First posted
Aug 10, 2018
StartActual
Jun 19, 2018
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03626038
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Jun 19, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion